Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2025 along with Statement of Assets and Liabilities and Cash Flow Statement
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong FY25 results, with standalone net sales rising about 30% to Rs. 45,170.62 lakhs from Rs. 34,657.69 lakhs a year ago. Standalone profit after tax grew roughly 33% to Rs. 2,080.76 lakhs (vs Rs. 1,562.34 lakhs), with basic EPS rising to Rs. 44.83 from Rs. 33.32. Q4 was also robust, with net sales of Rs. 16,543.76 lakhs and PAT of Rs. 707.18 lakhs. The board recommended a 7% final dividend (Rs. 0.70 per share). However, operating cash flow turned sharply negative at Rs. (2,888.33) lakhs, trade receivables nearly tripled to Rs. 17,712 lakhs, and short-term borrowings rose to Rs. 15,679 lakhs, pushing the debt-to-equity ratio above 1. The auditor issued an unmodified opinion but flagged a delay in transferring unclaimed dividends and shares to the IEPF for FY16 and FY17.
Strong top-line and earnings growth is positive for shareholders, supported by the 7% dividend. However, the deeply negative operating cash flow, surging receivables, and higher short-term debt raise concerns about working-capital strain and cash quality of profits. The IEPF transfer delay is a minor compliance red flag but does not affect the unqualified audit opinion.